This article is an erratum on:
First step results from a phase II study of a dendritic cell vaccine in glioblastoma patients (CombiG-vax)
An erratum on
First step results from a phase II study of a dendritic cell vaccine in glioblastoma patients (CombiG-vax)
By Ridolfi L, Gurrieri L, Riva N, Bulgarelli J, De Rosa F, Guidoboni M, Fausti V, Ranallo N, Calpona S, Tazzari M, Petrini M, Granato AM, Pancisi E, Foca F, Dall’Agata M, Bondi I, Amadori E, Cortesi P, Zani C, Ancarani V, Gamboni A, Polselli A, Pasini G, Bartolini D, Maimone G, Arpa D and Tosatto L (2024). Front. Immunol. 15:1404861. doi: 10.3389/fimmu.2024.1404861
Due to a production error, an author name was incorrectly spelled as “Monia D’Allagata”. The correct spelling is “Monia Dall’Agata”.
The publisher apologizes for this mistake.
The original version of this article has been updated.
Keywords: glioblastoma, vaccine, immunotherapy, dendritic cell, adoptive cell therapy, radiochemotherapy
Citation: Frontiers Production Office (2024) Erratum: First step results from a phase II study of a dendritic cell vaccine in glioblastoma patients (CombiG-vax). Front. Immunol. 15:1494021. doi: 10.3389/fimmu.2024.1494021
Received: 10 September 2024; Accepted: 10 September 2024;
Published: 19 September 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office, production.office@frontiersin.org